krs1

[TimAlerts] This probably didn't sit well with people on $THLD - "While the response observed in our squamous cell carcinoma of the skin study with tarloxotinib was encouraging, the overall results from the two studies didn't meet the activity thresholds required to move forward the molecule forward despite the promising results seen in preclinical translational studies,” said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "As a result, we are making no further investment in this program."

rmoj216

[TimAlerts] I can only assume that the thought or saying bad sushi... Has been said and well be said again when it comes to $THLD

Page
of 152